Haemophagocytic lymphohistiocytosis (HLH) is a potentially fatal condition in which abnormal activation of the immune system results in haemophagocytosis, inflammation and tissue damage. This results in a variety of signs and symptoms but most commonly fever, lymphadenopathy, splenomegaly, cytopenias, hyperferritinaemia and hypertriglyceridaemia. There are multiple reports of acquired HLH developing on a background of disseminated Mycobacterium infection. Simultaneously, since 2011, cases of invasive cardiovascular infection caused by Mycobacterium chimaera (M. chimaera) in patients having previously undergone cardiac surgery in Europe have been reported. We report a case of acquired HLH occurring one year after open-heart surgery to place a prosthetic valve due to M. chimaera.
Introduction
Mycobacterium Avium Complex (MAC) are a group of mycobacteria, which are found widely in the environment such as in soil and drinking water and are generally not harmful to the majority of healthy people [1] . They occasionally cause respiratory infections, or more fulminant infections in immunosuppressed individuals [1] . The US Food and Drug Administration (FDA) have recently issued an alert relating to the association of non-tuberculous mycobacterial infections such as MAC with heater-cooler devices primarily used in cardiothoracic surgical procedures [2] . The majority of cases have been prosthetic heart valves that have become infected either through contaminated water entering the devices or aerosolised bacteria transmitted through exhaust vents [2] . In some cases, patients presented with infections several months to years after their surgical procedure [2] [3] .
Hemophagocytic lymphohistiocytosis (HLH) is a frequently fatal and underdiagnosed disease involving a final common pathway of hypercytokinemia, which can result in end-organ damage and death [4] . Secondary HLH presents with a systemic inflammatory response syndrome (SIRS) and diagnosis requires five of the following eight criteria to be met; 1) fever, 2) cytopenia of two lines, 3) hypertriglyceridemia and/or hypofibrin-ogenemia, 4) hyperferritinemia (>500 microg/L), 5) hemophagocytosis, 6) elevated soluble interleukin-2 receptor (CD25), 7) decreased natural killer-cell activity, and 8) splenomegaly. There have been case reports confirming links between HLH and disseminated MAC or secondary to Mycobacterium tuberculous, however no documented case with M. chimaera [5] . Typical patient presentation involves unexplained fevers, weight loss and pancytopenia. We present a case of HLH secondary to M. chimaera infection of a prosthetic heart valve.
Case Presentation

Case History
A 72-year-old Caucasian gentleman was admitted to hospital with a progressive pancytopenia and a one-month history of unintentional weight loss and fevers (temperature >38˚). The patient had a past medical history of a prosthetic aortic valve replacement (AVR) for critical aortic stenosis in 2014. On clinical examination there was no stigmata of endocarditis with normal heart sounds however a spleen was palpable (Table 1) . In view of pancytopenia and splenomegaly, HLH was suspected and further biochemistry results showed an elevated ferritin 1677 ng/ml and triglyceride of 2.1 mg/dL. A bone marrow biopsy was performed, demonstrating the presence of numerous phagocytosing histiocytes suspicious of macrophage activation and non-necrotic microgra- nulomas raising concern for an infectious disease precipitant (Figure 1 ). Based on these findings our patient satisfied the clinical, laboratory and histopathological criteria for HLH (Table 2) .
Investigations
Radiological imaging only revealed mild splenomegaly with no occult malignancy and virology testing including Hepatitis B, C and HIV was negative. Microbiology investigations with serial peripheral blood cultures performed persistently isolated Mycobacterium Intracellulare, later confirmed to be M. chimaera.
Management and Case Progression
To combat the Mycobacterium infection, the patient was commenced on a prolonged course of combination of antibiotics including Clarithromycin, Rifampicin, Ethambutol and Amikacin. Intravenous Immunoglobulin (IVIg) was given weekly to inhibit haemophagocytosis, resulting in improvement in pancytopenia, hyperferritinaemia ( Figure   2 ) and constitutional symptoms. Despite the initial improvement in blood counts, the patient has remained moderately pancytopenic following one year follow up with recurrent septic episodes and is currently being managed palliatively.
Discussion
HLH is a potentially fatal condition in which abnormal activation of the immune system results in haemophagocytosis, inflammation and tissue damage [6] . 
